KORU MEDICAL SYSTEMS
Repro Med Systems, d/b/a KORU Medical (NASDAQ:KRMD), develops, manufactures, and commercializes innovative and easy-to-use at-home specialty infusion products that improve quality of life for patients around the world.
“The Equity Group took the time to understand the nuances of our business and corporate strategy. They asked the right questions, understood our needs and were very easy to work with. In just over year, they helped us evolve from an OTC-listed stock with a few institutional holders and no research coverage to a Nasdaq-listed company with nearly 60 institutional holders, a new name and brand, a successful offering and additional research coverage. They have managed all aspects of our IR plan, including written communications, investor and analyst outreach, conference presentations, etc.. They consistently demonstrate a strong work ethic, thoughtful approach, and real-world understanding of investor relations. The Equity Group has been a key component of our success.”
Don Pettigrew
Former President & CEO
Repro Med Systems d/b/a KORU Medical Systems (NASDAQ:KRMD)
THE START
  • Relationship commenced in March 2019.
  • The stock was trading on the OTC at approximately $1.50 per share, with a market cap of roughly $58 million.
  • The Company had no research coverage and two institutional holders.
Our Role
  • Created and implemented a strategic investor communications program that introduced structure and addressed weaknesses in messaging and disclosure. Our approach was informed by the long-term vision of the new management team and Board of Directors, the realities of the market, and the Company’s evolving business strategy.
  • Researched the business and industry, reviewed peer company disclosures, and interacted with Company executives and investors. We created a new investor presentation and a wide array of news releases that not only announced various corporate developments, but placed them in proper context of the Company’s long-term strategic vision.
  • Developed and managed a proactive investor/analyst outreach program, including numerous 1x1 meetings and calls and an array of national investor conferences (which we attended with management).
  • Drove/managed quarterly earnings events, including drafting the news release/script/deck, prepping for Q&A, and post-call follow-up.
  • Consulted on corporate re-branding.
  • Advised the Company regarding its planned uplisting, including appropriate exchange and earlier counsel where we advised management to attempt to meet the uplisting criteria naturally rather than pursuing a reverse split.
  • Arranged/attended two days of meetings surrounding the JP Morgan Healthcare Conference in San Francisco in January 2020.
  • Helped author COVID-19 messaging, with an emphasis on the “at home” advantages of the Company’s medical products.
  • Continued to arrange investor/analyst calls for management during the COVID-19 pandemic.
^
RESULTS
  • Craig-Hallum initiated research coverage of the Company in June 2019.
  • In October 2019, the stock reached $3.90 and the market cap was approximately $150 million.
  • KRMD uplisted to the NASDAQ in October 2019; we helped coordinate a bell-ringing event at the NASDAQ and associated media interviews.
  • KRMD had 58 institutional holders as of 3/31/20, including 22 with 50,000+ shares.
  • In June 2020, the Company completed a $29 million secondary offering; Piper Sandler & Co. and Canaccord Genuity LLC acted as joint bookrunning managers and Craig-Hallum Capital Group acted as lead manager. Several investor participants were originally introduced to the Company through our earlier IR efforts.
  • Stock price exceeded $9.00 and market cap topped $400 million in mid-2020.
PREVIOUS CASE STUDY
NEXT CASE STUDY